医疗器械ETF永赢(159883)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
-152,237,692.59 |
-10,491,083.26 |
-274,348,130.11 |
-348,412,825.90 |
| 利息合计 |
40,365.14 |
8,504.45 |
2,441,107.71 |
2,010,950.35 |
| 其中:存款利息收入 |
40,365.14 |
8,504.45 |
34,009.65 |
20,973.38 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-86,939,079.89 |
-75,129,745.12 |
-263,459,092.45 |
-173,199,053.76 |
| 其中:股票投资收益 |
-122,981,443.46 |
-92,048,098.45 |
-288,376,428.33 |
-186,573,197.12 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
36,042,363.57 |
16,918,353.33 |
24,917,335.88 |
13,374,143.36 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-71,826,547.60 |
64,299,454.68 |
-17,236,448.02 |
-179,330,292.75 |
| 其他收入 |
6,487,569.76 |
330,702.73 |
3,906,302.65 |
2,105,570.26 |
| 费用 |
17,300,709.59 |
5,109,257.48 |
10,686,758.97 |
5,508,045.13 |
| 管理人报酬 |
14,235,653.74 |
4,173,501.60 |
8,730,784.56 |
4,500,759.29 |
| 基金托管费 |
2,847,130.78 |
834,700.36 |
1,746,156.98 |
900,151.93 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
217,925.07 |
101,055.52 |
201,151.52 |
99,969.67 |
| 利润总额 |
-169,538,402.18 |
-15,600,340.74 |
-285,034,889.08 |
-353,920,871.03 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年